Here you can see and modify the cookie settings of various tools used on and related subdomains.

Save settings
Advantage Austria Show navigation

Dynamic biotech start-ups from Austria visit the UK to meet partners and investors

22. April 2013

On the 14th and 16th of May Austrian companies will present their technology showcases at Biotrinity - the UK’s largest gathering of the UK's Bioindustry and Europe's Fastest Growing Biopartnering and Investment Conference – which takes place at Newbury's Racecourse in Berkshire.

Biotrinity partners R&D companies and big pharma with biomedical investors and features showcases of the best of the UK and Europe's emerging and clinical stage companies.

The study trip starts one day before Biotrinity with visits planned to the European Medicines Agency, a tour around the life science department at Imperial College London and a seminar on investment opportunities in the United Kingdom at AdvantageAustria´s office in South Kensington.

If you are interested in meeting Austrian biotech companies determined researchers and entrepreneurs OR if you are an attendee of the Biotrinity Conference yourself please do get in touch via We look forward to hearing from you.

AUSTRIAN BIOTECHS attending and presenting Biotrinity Conference 14th-16th May 2013:

Short company descriptions are listed below - for full descriptions please click here - Austrian Biotechs [pdf, 305.7kb]

Akron Molecules - development of novel therapeutics for the treatment of human diseases with unmet medical need, including pain cancer and metabolic disease -

Dr Meng Pharma GmbH and INOXIA Lifesciences GmbH - development of treatment solutions for auto enzyme induced disease eg. Ulcerative colitis (UC) -

EUCODIS Bioscience - enzyme engineering company -

Haplogen - developing therapeutics to treat infectious diseases -
Lacerta Technologies GmbH
- developing a coating technology for bone grafts used to replace missing bones -

RECARDIO - Regenerative CARDIO-vascular Therapy - regenerative therapeutic modalities for the treatment of cardiovascular diseases -

Savira pharmaceuticals - development of drugs for the treatment of influenza -

Xiber Science - development of new peptide drugs to improve outcome of critical care & transplant patients -

Epherix Consulting -
Two Cluster Organisations will also join:
LISA Life Science Austria
Standortagentur Tirol  (in German)

To get in contact with our companies please call or email:

Marie-Katharine Traunfellner
Technology Key Account Manager
Austrian Embassy - Commercial Section
45 Princes Gate (Exhibition Road)
London SW7 2QA / United Kingdom
T +44 20 7584 4411